StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > I'm guessing it's been quiet because...

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Apr 08, 2021 4:11pm

82 Views

Post# 32958539

RE:RE:I'm guessing it's been quiet because...

I thought you sold. Welcome back

cactuseskimo wrote: You forgot to add that it cratered 50% in price in two days and also had the analyst rating drop from 4.00 to 1.25 after a colossal dissapointment. It's like you're desperately trying to perfume a skunk's a$$ to try and hide the smell or something. Honestly, the stock may go up, and if it does, great. But these kind of posts are what creates "bashers" in the first place. They just get sick of the rose-colored glasses pumping BS.

gojotv! wrote: ...investors are checking their accounts to see what they can free up to buy more here.
I know that's what I did earlier today.
Good financials, growing profits, frugal management, recent reverse-split has shrunken the share float, first to market with a multi-cancer blood panel and the first couple of thousand patients already lined up, acquired our own source of demand and follow-up capacity, an employer group strategy in the works, a toehold in the rapidly growing telehealth market, the list goes on and on...
Very happy with my choice. It sure smells like money to me!
GLTAll Investors!